Home » Topics » BioWorld Science

BioWorld Science
RSS

Almirall signs agreements with Ablexis and AliviaMab to support work in dermatology

Feb. 1, 2022

Ethris to advance mRNA-based therapeutics for respiratory diseases

Feb. 1, 2022

Loss of miR-15a/miR-16-1 contributes to CLL development

Feb. 1, 2022

Novel CDK9 inhibitor inhibits osteosarcoma in patient-derived orthotopic xenografts

Feb. 1, 2022

DDO-02005, a novel potent Kv1.5 potassium channel inhibitor with antiarrhythmic activity

Feb. 1, 2022

Acute intermittent porphyria treatment targets recombinant PBGD protein to the liver

Feb. 1, 2022

Researchers identify COPA as a prognostic marker and therapeutic target in cervical cancer

Feb. 1, 2022

Vitalixir presents new antidiabetic polypeptides

Feb. 1, 2022

Shenzhen Salubris Pharmaceuticals patents ADAM-TS 5 inhibitors

Feb. 1, 2022

Abbisko Therapeutics discovers EGFR inhibtors

Feb. 1, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...